GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Cash, Cash Equivalents, Marketable Securities

Tryptamine Therapeutics (ASX:TYP) Cash, Cash Equivalents, Marketable Securities : A$2.61 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Cash, Cash Equivalents, Marketable Securities?

Tryptamine Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (A$2.26 Mil) to Jun. 2023 (A$1.64 Mil) but then increased from Jun. 2023 (A$1.64 Mil) to Dec. 2023 (A$2.61 Mil).

Tryptamine Therapeutics's annual cash, cash equivalents, marketable securities declined from Jun. 2021 (A$12.72 Mil) to Jun. 2022 (A$4.85 Mil) and declined from Jun. 2022 (A$4.85 Mil) to Jun. 2023 (A$1.64 Mil).


Tryptamine Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Tryptamine Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 4.42 1.74 12.72 4.85 1.64

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 9.37 4.85 2.26 1.64 2.61

Tryptamine Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Tryptamine Therapeutics  (ASX:TYP) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Tryptamine Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics (ASX:TYP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines